Method for treating pervasive development disorders

• US 9,624,525 B2
• Filed: 12/07/2011
• Issued: 04/18/2017
• Est. Priority Date: 12/17/1999
• Status: Expired due to Fees

• Current Assignee: Curemark LLC
• Original Assignee: Curemark LLC
• Inventors: Fallon, Joan M.
• Primary Examiner(s): BALLARD, KIMBERLY
• Application Number:
  US13/313,629
• Publication Number:
  US 20120114562A1
• Time in Patent Office: 1,959 Days
• CPC Class Codes: A61B 5/1118 Determining activity level
• CPC Class Codes: A61B 5/16 Devices for psychotechnics using teaching or educational appliances G09B1/00 - G09B7/00; Testing reaction times ; Devices for evaluating the psychological state
• CPC Class Codes: A61B 5/165 Evaluating the state of mind, e.g. depression, anxiety
• CPC Class Codes: A61B 5/4848 Monitoring or testing the effects of treatment, e.g. of medication
• CPC Class Codes: A61K 38/2235 Secretins
• CPC Class Codes: A61K 38/465 acting on ester bonds (3.1), e.g. lipases, ribonucleases
• CPC Class Codes: A61K 38/47 acting on glycosyl compounds (3.2), e.g. cellulases, lactases
• CPC Class Codes: A61K 38/48 acting on peptide bonds (3.4)
• CPC Class Codes: A61K 38/4826 Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/20 Pills, tablets, discs, rods A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095
• CPC Class Codes: A61P 1/18 for pancreatic disorders, e.g. pancreatic enzymes
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: C12Q 1/37 involving peptidase or proteinase
• CPC Class Codes: C12Y 302/0102 Alpha-glucosidase (3.2.1.20)
• CPC Class Codes: C12Y 304/21001 Chymotrypsin (3.4.21.1)
• CPC Class Codes: C12Y 304/21004 Trypsin (3.4.21.4)
• CPC Class Codes: G01N 2333/976 Trypsin; Chymotrypsin
• CPC Class Codes: Y10S 435/803 Physical recovery methods, e.g. chromatography, grinding
• CPC Class Codes: Y10T 436/24 Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Abstract

A method of utilizing the chymotrypsin level of an individual as a measure of the success of neuropeptides, and peptides or digestive enzyme administration to such individuals, and in particular, as a prognosticative of potential neuropeptides, peptides, and digestive enzyme administration for persons having ADD, ADHD, Autism and other PDD related disorders. A method for determining the efficacy of neuropeptides, peptides, or digestive enzymes for the treatment of an individual diagnosed with a pervasive developmental disorder (PDD) comprises obtaining a sample of feces from an individual, determining a quantitative level of chymotrypsin present in the sample, and correlating the quantitative level of chymotrypsin determined to be present in the sample with the PDD to determine the efficacy of treating the individual with neuropeptides, peptides, or digestive enzyme administration.

Claims

1. A method for determining if an individual having a Pervasive Developmental Disorder (PDD) and a subnormal level of fecal chymotrypsin has improved after administration of a dose of digestive enzymes;

the method comprising;

a) making a quantitative pre-administration measurement of a symptom of a PDD and measuring a pre-administration level of fecal chymotrypsin in the individual;

b) administering to the individual a dose of digestive enzymes if the individual has a subnormal level of fecal chymotrypsin, wherein the digestive enzymes comprise a protease, an amylase and a lipase;

c) making a quantitative post-administration measurement of the symptom of the PDD and measuring a post-administration level of fecal chymotrypsin in the individual; and

d) comparing the quantitative post-administration measurement of the symptom of the PDD to a quantitative pre-administration measurement of the symptom of the PDD,

wherein a decrease in the quantitative post-administration measurement of the symptom compared to the quantitative pre-administration of the symptom indicates the PDD has improved.

2. The method of claim 1, wherein the quantitative, post-administration measurement measures social behavior.

3. The method of claim 1, wherein the quantitative, post-administration measurement measures imitation.

4. The method of claim 1, wherein the quantitative, post-administration measurement measures body use.

5. The method of claim 1 wherein the quantitative, post-administration measurement measures object use.

6. The method of claim 1, wherein the quantitative, post-administration measurement measures adaptation to change.

7. The method of claim 1 wherein the quantitative, post-administration measurement measures visual response.

8. The method of claim 1, wherein the quantitative, post-administration measurement measures listening response.

9. The method of claim 1, wherein the quantitative, post-administration measurement measures taste, smell, touch response and use.

10. The method of claim 1, wherein the quantitative, post-administration measurement measures fear.

11. The method of claim 1, wherein the quantitative, post-administration measurement measures verbal communication.

12. The method of claim 1, wherein the quantitative, post-administration measurement measures non-verbal communication.

13. The method of claim 1, wherein the quantitative, post-administration measurement measures activity level.

14. The method of claim 1, wherein the measurement is a quantitative measurement of general impression.

15. The method of claim 1, wherein the quantitative, post-administration measurement is a Childhood Autism Rating Scale measurement.

16. The method of claim 1, wherein the digestive enzymes comprise a protease that comprises chymotrypsin or trypsin.

17. The method of claim 1, wherein measuring a pre-administration level of fecal chymotrypsin comprises enzyme spectrophotometry.

18. The method of claim 1, wherein measuring a post-administration level of fecal chymotrypsin comprises enzyme spectrophotometry.

19. A method for determining if an individual having a Pervasive Developmental Disorder (PDD) and a subnormal level of fecal chymotrypsin has improved after administration of a dose of digestive enzymes;

the method comprising;

a) making a quantitative pre-administration measurement of a symptom of a PDD and measuring a pre-administration level of fecal chymotrypsin in the individual;

b) administering to the individual a dose of digestive enzymes if the individual has a subnormal level of fecal chymotrypsin, wherein the digestive enzymes comprise a protease, an amylase and a lipase;

c) making a quantitative post-administration measurement of the symptom of the PDD and measuring a post-administration level of fecal chymotrypsin in the individual; and

d) comparing the quantitative post-administration measurement of the symptom of the PDD to a quantitative pre-administration measurement of the symptom of the PDD,

wherein an improvement in the quantitative post-administration measurement of the symptom compared to the quantitative pre-administration of the symptom indicates that the PDD has improved.

20. The method of claim 19, wherein the quantitative, post-administration measurement measures social behavior.

21. The method of claim 19, wherein the quantitative, post-administration measurement measures imitation.

22. The method of claim 19, wherein the quantitative, post-administration measurement measures visual response.

23. The method of claim 19, wherein the quantitative, post-administration measurement measures listening response.

24. The method of claim 19, wherein the quantitative, post-administration measurement measures taste, smell, touch response and use.

25. The method of claim 19, wherein the quantitative, post-administration measurement is a Childhood Autism Rating Scale measurement.

26. The method of claim 19, wherein the digestive enzymes comprise a protease that comprises chymotrypsin or trypsin.

27. The method of claim 19, wherein measuring a pre-administration level of fecal chymotrypsin comprises enzyme spectrophotometry.

28. The method of claim 19, wherein measuring a post-administration level of fecal chymotrypsin comprises enzyme spectrophotometry.